TWI851584B - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
TWI851584B
TWI851584B TW108122117A TW108122117A TWI851584B TW I851584 B TWI851584 B TW I851584B TW 108122117 A TW108122117 A TW 108122117A TW 108122117 A TW108122117 A TW 108122117A TW I851584 B TWI851584 B TW I851584B
Authority
TW
Taiwan
Prior art keywords
formula
compound
compounds
group
spp
Prior art date
Application number
TW108122117A
Other languages
English (en)
Chinese (zh)
Other versions
TW202019949A (zh
Inventor
潘美拉 布朗
麥克 道森
蒙娜 西莫諾維克
史帝芬 布克斯
伊斯特 杜波奇
狄恩 李佛斯
羅伊 李斯特
史考特 柯爾曼
Original Assignee
新加坡商雲頂新耀股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新加坡商雲頂新耀股份有限公司 filed Critical 新加坡商雲頂新耀股份有限公司
Publication of TW202019949A publication Critical patent/TW202019949A/zh
Application granted granted Critical
Publication of TWI851584B publication Critical patent/TWI851584B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108122117A 2018-06-25 2019-06-25 化合物 TWI851584B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
US62/689,602 2018-06-25

Publications (2)

Publication Number Publication Date
TW202019949A TW202019949A (zh) 2020-06-01
TWI851584B true TWI851584B (zh) 2024-08-11

Family

ID=67107423

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108122117A TWI851584B (zh) 2018-06-25 2019-06-25 化合物
TW113126533A TW202446783A (zh) 2018-06-25 2019-06-25 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113126533A TW202446783A (zh) 2018-06-25 2019-06-25 化合物

Country Status (31)

Country Link
US (3) US11459357B2 (enExample)
EP (2) EP3810633B1 (enExample)
JP (2) JP7488774B2 (enExample)
KR (1) KR20210054500A (enExample)
CN (2) CN118878638A (enExample)
AR (1) AR116663A1 (enExample)
AU (2) AU2019294261B2 (enExample)
BR (1) BR112020026663A2 (enExample)
CA (1) CA3103158A1 (enExample)
CO (1) CO2020016080A2 (enExample)
DK (1) DK3810633T3 (enExample)
EA (1) EA202092819A1 (enExample)
ES (1) ES2971732T3 (enExample)
FI (1) FI3810633T3 (enExample)
HR (1) HRP20240028T1 (enExample)
HU (1) HUE065134T2 (enExample)
IL (2) IL279620B2 (enExample)
LT (1) LT3810633T (enExample)
MA (1) MA52946B1 (enExample)
MD (1) MD3810633T2 (enExample)
MX (1) MX2020013811A (enExample)
PH (1) PH12020552240A1 (enExample)
PL (1) PL3810633T3 (enExample)
PT (1) PT3810633T (enExample)
RS (1) RS65128B1 (enExample)
SG (1) SG11202012747VA (enExample)
SI (1) SI3810633T1 (enExample)
TW (2) TWI851584B (enExample)
UA (1) UA128162C2 (enExample)
WO (1) WO2020002325A1 (enExample)
ZA (1) ZA202301937B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN120574287B (zh) * 2025-06-10 2026-07-03 中国药科大学 一种抗菌肽、组合物及应用
CN121159640A (zh) * 2025-07-24 2025-12-19 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201617362A (zh) * 2014-03-11 2016-05-16 新製藥授權控股公司 化合物
TW201625664A (zh) * 2014-11-26 2016-07-16 新製藥授權控股公司 化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
BR112017010888A2 (pt) * 2014-12-17 2018-02-27 Hoffmann La Roche método para produzir um produto de conjugação enzimática de três polipeptídeos
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201617362A (zh) * 2014-03-11 2016-05-16 新製藥授權控股公司 化合物
TW201625664A (zh) * 2014-11-26 2016-07-16 新製藥授權控股公司 化合物

Also Published As

Publication number Publication date
CN118878638A (zh) 2024-11-01
MA52946A (fr) 2021-04-28
IL279620B1 (en) 2025-11-01
RS65128B1 (sr) 2024-02-29
WO2020002325A1 (en) 2020-01-02
US20230012121A1 (en) 2023-01-12
EA202092819A1 (ru) 2021-05-21
MX2020013811A (es) 2021-03-09
NZ771833A (en) 2024-09-27
JP2021528449A (ja) 2021-10-21
MD3810633T2 (ro) 2024-05-31
CA3103158A1 (en) 2020-01-02
HRP20240028T1 (hr) 2024-03-29
IL279620B2 (en) 2026-03-01
LT3810633T (lt) 2024-01-10
EP4316504A2 (en) 2024-02-07
IL323560A (en) 2025-11-01
US20260103491A1 (en) 2026-04-16
BR112020026663A2 (pt) 2021-03-23
CN112789287B (zh) 2024-06-21
US20210246169A1 (en) 2021-08-12
ZA202301937B (en) 2023-09-27
TW202446783A (zh) 2024-12-01
HUE065134T2 (hu) 2024-05-28
MA52946B1 (fr) 2024-03-29
FI3810633T3 (fi) 2024-02-09
AU2019294261A1 (en) 2021-02-04
SI3810633T1 (sl) 2024-04-30
CO2020016080A2 (es) 2021-01-18
PH12020552240A1 (en) 2021-08-16
EP3810633B1 (en) 2023-12-13
AU2024203362A1 (en) 2024-06-06
AR116663A1 (es) 2021-06-02
JP2024109664A (ja) 2024-08-14
DK3810633T3 (da) 2024-01-15
US11459357B2 (en) 2022-10-04
EP3810633A1 (en) 2021-04-28
ES2971732T3 (es) 2024-06-06
US12528837B2 (en) 2026-01-20
TW202019949A (zh) 2020-06-01
AU2019294261B2 (en) 2024-02-29
PT3810633T (pt) 2024-02-19
EP4316504A3 (en) 2024-04-17
SG11202012747VA (en) 2021-01-28
PL3810633T3 (pl) 2024-04-08
IL279620A (en) 2021-03-01
JP7488774B2 (ja) 2024-05-22
CN112789287A (zh) 2021-05-11
UA128162C2 (uk) 2024-04-24
KR20210054500A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
JP7488774B2 (ja) 化合物
JP6643758B2 (ja) 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
KR20140091724A (ko) 폴리믹신 유도체
JP7349773B2 (ja) 化合物
HK40098322A (en) Compounds
EA047835B1 (ru) Соединения
HK40040020A (en) Compounds
HK40040020B (en) Compounds
TW202233649A (zh) 化合物
JP2025505237A (ja) 抗生物質化合物、製剤および使用方法
BR112016020998B1 (pt) Compostos derivados de polimixina, composições farmacêuticas compreendedo os ditos compostos e usos terapêuticos dos mesmos